Investor
Davern Capital Partners, LP
CIK 0002003147 · filed 2026-05-14 · SEC filing
13F book
$364.5M
Positions
17
4 new · 1 sold
Largest name
12.3%
Pfizer Inc · PFE
Est. mark
−$5.11M
Price effect on 13 names still held. Flow $60.4M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Pfizer Inc | PFE | 1.59M | $44.8M | 12.3% | $5.07M | Cut−$6.09M |
| Regeneron Pharmaceuticals, Inc. | REGN | 44.8K | $34.6M | 9.5% | $34.5K | Cut−$5.85M |
| Insmed Inc | INSM | 182.6K | $29.9M | 8.2% | — | New |
| Ionis Pharmaceuticals Inc | IONS | 386.9K | $29.1M | 8.0% | −$958.7K | Added$10.2M |
| Natera, Inc. | NTRA | 144K | $28.8M | 7.9% | −$2.29M | Added$10.8M |
| Biontech Se | BNTX | 305.1K | $27.1M | 7.4% | −$1.93M | Cut−$8.23M |
| Argenx SE | ARGX | 35K | $25.6M | 7.0% | −$3.88M | Cut−$4.42M |
| Eli Lilly & Co | LLY | 27.3K | $25.1M | 6.9% | −$1.29M | Added$16.2M |
| Royalty Pharma PLC | RPRX | 520K | $24.9M | 6.8% | $4.85M | Cut−$7.54M |
| Roivant Sciences Ltd. | ROIV | 873.4K | $24.2M | 6.6% | $5.24M | Cut$1.88M |
| Legend Biotech Corp | LEGN | 1.31M | $23.8M | 6.5% | −$3.86M | Added$811.8K |
| Mineralys Therapeutics, Inc. | MLYS | 447.2K | $12.1M | 3.3% | −$1.94M | Added$4.47M |
| Abivax Sa | — | 78.1K | $8.7M | 2.4% | −$1.14M | Added$2.16M |
| Generate Biomedicines, Inc. | GENB | 591.8K | $7.4M | 2.0% | — | New |
| Procept Biorobotics Corp | PRCT | 261.2K | $6.53M | 1.8% | — | New |
| Structure Therapeutics Inc. | GPCR | 126.5K | $6.1M | 1.7% | — | New |
| Viridian Therapeutics Inc | — | 302.5K | $5.92M | 1.6% | −$3.02M | Added−$2.23M |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.